No Data
No Data
PYC Therapeutics Progresses Objective of Becoming Commercial-Stage Drug Developer; Shares Rise 6%
PYC Therapeutics Target Price Cut 23% to A$3.00/Share by Wilsons>PYC.AU
PYC Therapeutics Says First Subject Receives Kidney Disease Drug Candidate in Phase 1 Trial
PYC Therapeutics Posts Wider Fiscal H1 Loss, Higher Revenue
PYC Therapeutics Ltd: Half Yearly Report and Accounts
PYC Therapeutics to Raise Nearly AU$146 Million via Entitlement Offer
茁壮成长的韭菜 : Concerns about tariffs and the recession in the USA mean that there are no techniques applicable to Stocks. With economic stability on the rise, it is still possible to analyze the fundamentals of Stocks. At this moment, it's about whether to run or not.
Cracker13 OP 茁壮成长的韭菜 : yes, so I have worked out haha